|
Does a longer waiting period after neoadjuvant radiochemotherapy improve the oncological prognosis of rectal cancer?: Three-year follow-up results of the GRECCAR-6 randomized multicenter trial. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Sanofi |
Speakers' Bureau - Amgen; Lilly; Merck Serono; Roche; Sanofi |
Travel, Accommodations, Expenses - Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Hospira |
|
|
Research Funding - Merck Serono |
Travel, Accommodations, Expenses - Amgen; Merck Serono |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer Schering Pharma; Bristol-Myers Squibb; Merck Sharp & Dohme; Sanofi |
Research Funding - AstraZeneca; Daiichi Sankyo; GlaxoSmithKline; Merck Sharp & Dohme; Novartis; Sanofi |
|
|
Travel, Accommodations, Expenses - Brothier; Eumedica; Pharmacie Cousin; Sanofi |